
Bob Safian interviews Ben Lamm, the CEO of Colossal Biosciences, about the company's work on de-extinction, specifically focusing on the resurrection of the dire wolf. Lamm explains the science behind their work, which involves tweaking the DNA of existing gray wolves to match that of ancient dire wolves, addressing controversies and ethical concerns surrounding de-extinction, and the potential for this technology to aid in species conservation. They also discuss the business model of Colossal, its celebrity investors, and the broader implications of synthetic biology, including potential applications in human health and the need for ethical guardrails.
Sign in to continue reading, translating and more.
Continue